Marvel Biosciences Selected to Present Alzheimer's Research at the 2025 Alzheimer's Association International Conference
Marvel Biosciences (TSXV: MRVL) (OTCQB: MBCOF) has been selected to present groundbreaking Alzheimer's disease research at the prestigious Alzheimer's Association International Conference in July 2025.
The presentation will showcase preclinical data from their acute Alzheimer's study, conducted with Professor Emmanuel Planel, focusing on their compound MB-204. The research demonstrated significant reduction in tau hyperphosphorylation in mice, suggesting potential as a disease-modifying therapy.
Additionally, Marvel is conducting a chronic Alzheimer's study using the 5xFAD model, backed by an Alberta Innovates grant. This ongoing research evaluates MB-204's effects on cognition, behavior, and disease pathology, with results expected in Q3 2025.
Marvel Biosciences (TSXV: MRVL) (OTCQB: MBCOF) è stata selezionata per presentare una ricerca innovativa sulla malattia di Alzheimer alla prestigiosa Conferenza Internazionale dell'Associazione Alzheimer nel luglio 2025.
La presentazione metterà in evidenza i dati preclinici del loro studio acuto sull'Alzheimer, condotto con il Professor Emmanuel Planel, focalizzandosi sul loro composto MB-204. La ricerca ha dimostrato una significativa riduzione della iperfosforilazione della tau nei topi, suggerendo il potenziale come terapia modificante la malattia.
Inoltre, Marvel sta conducendo uno studio cronico sull'Alzheimer utilizzando il modello 5xFAD, supportato da un finanziamento di Alberta Innovates. Questa ricerca in corso valuta gli effetti di MB-204 sulla cognizione, sul comportamento e sulla patologia della malattia, con risultati attesi nel terzo trimestre del 2025.
Marvel Biosciences (TSXV: MRVL) (OTCQB: MBCOF) ha sido seleccionada para presentar una investigación innovadora sobre la enfermedad de Alzheimer en la prestigiosa Conferencia Internacional de la Asociación de Alzheimer en julio de 2025.
La presentación mostrará datos preclínicos de su estudio agudo sobre Alzheimer, realizado con el Profesor Emmanuel Planel, centrándose en su compuesto MB-204. La investigación demostró una reducción significativa en la hiperfosforilación de tau en ratones, sugiriendo un potencial como terapia modificadora de la enfermedad.
Además, Marvel está llevando a cabo un estudio crónico sobre Alzheimer utilizando el modelo 5xFAD, respaldado por una subvención de Alberta Innovates. Esta investigación en curso evalúa los efectos de MB-204 en la cognición, el comportamiento y la patología de la enfermedad, con resultados esperados en el tercer trimestre de 2025.
Marvel Biosciences (TSXV: MRVL) (OTCQB: MBCOF)는 2025년 7월에 열리는 권위 있는 알츠하이머 협회 국제 회의에서 혁신적인 알츠하이머병 연구를 발표하도록 선정되었습니다.
이번 발표에서는 Emmanuel Planel 교수와 함께 진행한 급성 알츠하이머 연구의 전임상 데이터를 선보이며, 그들의 화합물 MB-204에 초점을 맞출 것입니다. 연구 결과, 생쥐에서 tau의 과인산화가 유의미하게 감소했으며, 이는 질병 수정 요법으로서의 잠재력을 시사합니다.
또한, Marvel은 Alberta Innovates의 지원을 받아 5xFAD 모델을 사용하여 만성 알츠하이머 연구를 진행하고 있습니다. 이 연구는 MB-204가 인지, 행동 및 질병 병리에 미치는 영향을 평가하며, 2025년 3분기에 결과가 예상됩니다.
Marvel Biosciences (TSXV: MRVL) (OTCQB: MBCOF) a été sélectionnée pour présenter des recherches révolutionnaires sur la maladie d'Alzheimer lors de la prestigieuse Conférence Internationale de l'Association Alzheimer en juillet 2025.
La présentation mettra en avant des données précliniques de leur étude aiguë sur Alzheimer, réalisée avec le Professeur Emmanuel Planel, en se concentrant sur leur composé MB-204. La recherche a démontré une réduction significative de l'hyperphosphorylation de la tau chez les souris, suggérant un potentiel en tant que thérapie modifiant la maladie.
De plus, Marvel mène une étude chronique sur Alzheimer utilisant le modèle 5xFAD, soutenue par une subvention d'Alberta Innovates. Cette recherche en cours évalue les effets de MB-204 sur la cognition, le comportement et la pathologie de la maladie, avec des résultats attendus au troisième trimestre 2025.
Marvel Biosciences (TSXV: MRVL) (OTCQB: MBCOF) wurde ausgewählt, um bahnbrechende Forschung zur Alzheimer-Krankheit auf der renommierten Internationalen Alzheimer-Konferenz im Juli 2025 zu präsentieren.
Die Präsentation wird präklinische Daten aus ihrer akuten Alzheimer-Studie zeigen, die in Zusammenarbeit mit Professor Emmanuel Planel durchgeführt wurde, wobei der Fokus auf ihrem Wirkstoff MB-204 liegt. Die Forschung zeigte eine signifikante Reduktion der Tau-Hyperphosphorylierung bei Mäusen, was auf ein Potenzial als krankheitsmodifizierende Therapie hinweist.
Zusätzlich führt Marvel eine chronische Alzheimer-Studie mit dem 5xFAD-Modell durch, die von einem Alberta Innovates-Stipendium unterstützt wird. Diese laufende Forschung bewertet die Auswirkungen von MB-204 auf Kognition, Verhalten und Krankheitspathologie, mit Ergebnissen, die im dritten Quartal 2025 erwartet werden.
- None.
- None.
Calgary, Alberta--(Newsfile Corp. - April 14, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), is pleased to announce that it has been invited to present its latest research findings at the Alzheimer's Association International Conference (AAIC), taking place in July 2025.
The Company will present preclinical data from its acute Alzheimer's disease study, conducted in collaboration with Professor Emmanuel Planel, a global expert in tau pathology. This research demonstrated MB-204's ability to significantly reduce tau hyperphosphorylation in mice - a core aspect of Alzheimer's disease - highlighting MB-204's potential as a disease-modifying therapy.
"We are honoured to be presenting at the world's leading forum for Alzheimer's research," said Dr. Mark Williams, Chief Scientific Officer of Marvel Biosciences. "Our data suggest MB-204 may offer a novel approach to targeting tau pathology in Alzheimer's disease."
For additional context, please refer to our earlier announcement detailing MB-204's impact on tau phosphorylation: https://marvelbiotechnology.com/marvel-biosciences-announces-positive-interim-results-on-tau-phosphorylation-with-mb-204/
In addition to the acute study findings, Marvel is currently conducting a chronic Alzheimer's disease study in the 5xFAD model, supported by a grant from Alberta Innovates. This ongoing study will evaluate MB-204's effect on cognition, behavior, and disease pathology in a validated mouse model. Results are expected in Q3 2025.
About Marvel Biosciences Corp.
Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary- based pre-clinical stage pharmaceutical development biotechnology company. The Company is developing MB-204, a novel fluorinated derivative of the approved anti-Parkinson's drug Istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer's Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.
Contact Information:
Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/248248
FAQ
What breakthrough did Marvel Biosciences (MBCOF) achieve in their Alzheimer's research?
When will Marvel Biosciences (MBCOF) present at the Alzheimer's Association International Conference?
What is the timeline for Marvel Biosciences' (MBCOF) chronic Alzheimer's study results?
Who is collaborating with Marvel Biosciences (MBCOF) on their Alzheimer's research?
What funding support has Marvel Biosciences (MBCOF) received for their Alzheimer's research?
